MedulAI, the first Spanish artificial intelligence system for the digitisation and cytological analysis of bone marrow, has officially launched and is already in use across 14 hospitals in Spain. MedulAI was created and is owned by SpotLab. The Sociedad Española de Hematología y Hemoterapia (SEHH) and GSK partner to help introduce it into Spain’s National Health System (SNS).
At a glance
- What it is: the first Spanish AI system for the digitisation and cytological analysis of bone marrow
- Partners: the SEHH and GSK, who help introduce MedulAI into Spain’s National Health System, within the GSK Gate2Health programme
- Reach: in use across 14 hospitals in seven autonomous communities
- Evidence base: trained on more than 6 million cells and backed by 18 scientific publications
- Potential impact: AI can reduce the time spent on sample analysis in haematology by up to 80%
- Contact: medulai@spotlab.ai
What is MedulAI?
MedulAI is the first Spanish artificial intelligence system for the digitisation and cytological analysis of bone marrow. It is trained on more than 6 million cells, backed by 18 scientific publications, and already in use across 14 hospitals in Spain.
Its purpose is to put artificial intelligence at the service of clinical judgement. MedulAI helps optimise diagnostic processes, reduce variability between observers, and enable more consistent access to haematological digitisation.
Why does MedulAI matter?
Fast, high-quality diagnosis should not depend on the size of your hospital. MedulAI brings reliable, sovereign and secure artificial intelligence to any centre, large or small, so that diagnostic quality reaches every patient equally.
The potential is significant. Artificial intelligence can reduce the time spent on sample analysis in haematology by up to 80%, freeing specialist time and strengthening patient care.
Who created MedulAI?
MedulAI was created and is owned by SpotLab, the company behind its technology. The Sociedad Española de Hematología y Hemoterapia (SEHH) and GSK partner to help introduce MedulAI into the Spanish National Health System (SNS). This collaboration forms part of GSK Gate2Health, GSK’s open innovation programme that supports digital transformation projects in healthcare.
What is MedulAI’s reach in Spain?
MedulAI is in use across 14 centres in seven autonomous communities. This participation highlights its national scope and the growing interest of the haematology community in adopting digital and artificial intelligence tools in clinical practice.
Participating centres:
- Hospital Universitario Ramón y Cajal
- Hospital Universitario La Paz
- Hospital Universitario Fundación Jiménez Díaz
- Hospital Universitario Infanta Leonor
- Hematoclin Médico
- Hospital Universitario Virgen del Rocío
- Hospital Universitario Reina Sofía
- Hospital Nuestra Señora de Sonsoles
- Hospital Universitario Nuestra Señora de Candelaria
- Hospital General Universitario de Elche
- Institut Català d’Oncologia (ICO)
- Parc Taulí Hospital Universitari
- Hospital del Mar
- Hospital Universitario Son Llàtzer
The launch event
At the presentation of MedulAI, haematologists, healthcare leaders and innovation managers shared a day of reflection on the present and future challenges of the specialty. The event reinforced a commitment to collaboration and responsible innovation as levers towards more precise, connected and future-ready healthcare.
Explore MedulAI in your clinical practice
Want to find out what MedulAI can bring to your clinical practice? Write to us at medulai@spotlab.ai and we will explain how to integrate it into your centre.
Frequently asked questions
What is MedulAI? MedulAI is the first Spanish artificial intelligence system for the digitisation and cytological analysis of bone marrow. It is trained on more than 6 million cells, backed by 18 scientific publications, and in use across 14 hospitals in Spain.
Who created MedulAI? MedulAI was created and is owned by SpotLab. The Sociedad Española de Hematología y Hemoterapia (SEHH) and GSK partner to help introduce it into the Spanish National Health System, as part of the GSK Gate2Health programme.
In how many hospitals is MedulAI in use? MedulAI is in use across 14 hospitals in seven autonomous communities in Spain.
What is GSK Gate2Health? GSK Gate2Health is GSK’s open innovation programme that supports digital transformation projects in healthcare. MedulAI is one of the initiatives driven through this programme.
How can I try MedulAI in my hospital? By writing to medulai@spotlab.ai, where the team explains what MedulAI can bring to your clinical practice and how to integrate it into your centre.